Extract
Pulmonary hypertension (PH) is a highly morbid disease defined foremost by elevated mean pulmonary artery pressure (mPAP) measured during right heart catheterisation (RHC) at rest. Patients are classified further into one of three PH haemodynamic subgroups based on specific pulmonary artery wedge pressure (PAWP) and pulmonary vascular resistance (PVR) thresholds: pre-capillary PH (PAWP ≤15 mmHg+PVR ≥3.0 Wood units (WU)), isolated post-capillary PH (PAWP >15 mmHg+PVR <3.0 WU) and combined pre-/post-capillary PH (PAWP >15 mmHg+PVR ≥3.0 WU) [1].
Abstract
These data illustrate the risk continuum based on multiple right heart catheterisation measurements when modelled together, but also identify pulmonary artery wedge pressure >15 mmHg and <12 mmHg as particularly high risk https://bit.ly/3whDEOV
Footnotes
Data availability: The data from the study cohort that support the findings of this study are available from the corresponding author on reasonable request, although they will be subject to the stringent data privacy rules of the Veterans Affairs Healthcare System and the US Government.
Conflict of interest: W.M. Oldham has nothing to disclose.
Conflict of interest: E. Hess has nothing to disclose.
Conflict of interest: S.W. Waldo reports other (research grants to the Denver Research Institute) from Abiomed, Cardiovascular Systems Incorporated and Janssen Pharmaceuticals, outside the submitted work.
Conflict of interest: M. Humbert reports personal fees from Actelion, Acceleron, Bayer and Merck, outside the submitted work.
Conflict of interest: G. Choudhary has nothing to disclose.
Conflict of interest: B.A. Maron reports personal fees from Actelion, outside the submitted work; and has a US patent 9,605,047 issued, US patent PCT/US2019/059890 pending, and provisional patent applications 62475955 and 029672 pending.
Support statement: B.A. Maron: R01HL139613-01, R01HL1535-02, R01HL155096-01, U54HL119145, R21HL145420; Cardiovascular Medical Research Education Foundation (CMREF), and McKenzie Family Charitable Trust, Boston Biomedical Innovations Center. W.M. Oldham: K08HL128802, CMREF; G. Choudhary: VA CSR&D grant I01CX001892, and NHLBI R01HL148727. Funding information for this article has been deposited with the Crossref Funder Registry. The views expressed are those of the authors alone and do not represent the views of the Veterans Affairs or other US federal government agencies.
- Received December 23, 2020.
- Accepted March 27, 2021.
- The content of this work is not subject to copyright. Design and branding are copyright ©ERS 2021. For commercial reproduction rights and permissions contact permissions{at}ersnet.org